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THE IDENTIFICATION of an individual
patient's methotrexate (MTX) absorption
characteristics would be of clinical value
if this could be used either to anticipate
toxicity or to indicate inadequate absorp-
tion. The therapeutic range of MTX blood
levels is currently unknown. It is not
clear whether either response or prognosis
depends upon the magnitude of the peak
level, the duration for which a critical
level is exceeded, or the total amount of
drug absorbed as indicated by the area
under the absorption curve. It has recently
been suggested that the rate of absorption
may be an important factor, with the slow
absorber having a high relapse rate (Craft,
1979 Int. Symp. Methotrexate).
Variations in the absorption of orally
administeredMTX were firstdemonstrated
by Freeman-Narrod (1962) who suggested
that patients could be divided into fast
and slow absorbers based upon the serum
MTX level 1 h after administration. The
slow absorber had a low peak level, but
MTX was detectable for a prolonged
period, often associated with mucosal
ulceration. An association between pro-
longed MTX therapy and drug malabsorp-
tion has been suggested (Freeman-Narrod,
1962; Craft, 1977) since this drug is known
to affect small intestinal structure (Trier,
1962) and function (Craft, 1977; Venho,
1976).
Previous studies of MTX absorption
have been poorly standardized with regard
to the dose ofMTX and its relationship to
food and other oral medication (Freeman-
Narrod, 1962; Kierney, 1979; Boomla,
1979). In this study these factors were
carefully standardized, andtheearlyserum
profile of MTX was measured in a group
of leukaemic children.
Twenty children with acute lympho-
blastic leukaemia (ALL) were studied,
10 of whom were males. Their ages ranged
from 3 to 16 years and the duration on
therapy from 3 to 36 months. All were
managed according to the Medical Re-
search Council's Working Party on Leu-
kaemia in Childhood (UKALL trials)
and were receiving MTX either as a single
weekly dose or as a 5-day course every
3 weeks. No other therapy was given for
at least 5 days prior to investigation.
Patients were fasted from 20:00 hours
andnextmorning afinevenouscannulawas
inserted. A resting blood sample was taken
and oral MTX (15 mg/M2) given with 20 ml
water. Blood samples were taken at 20-
min intervals for the first hour and hourly
thereafter up to 5 h. Serum was separated
within 6 h of sampling and stored at
-20°C. Samples were analysed within 2
weeks by enzyme-linked immunoassay
(Emit MTX assay, Silva, Maidenhead);
levels less than 0-2 ,uM were assayed by
Correspondence to: Dr C. R. Pinkerton, DepartmentofChild Health, Institute ofClinical Science, Grosvenor
Road, Belfast BT12 6BJ, Northern Ireland.C. R. PINKERTON ET AL.
1.4
1.2
1.0
i :.
x
-
w X
en
0.9 [
0.6 [
0.4k
0.2F
1.6
1.4
1.2
_ 1.0 i :3-
x
I 0.8
W 0.6
0.44
0.4
0.2 0 1 2 3 4
TIME (h)
FIG. 1.-Mean serum MTX concentration
+s.d. in 20 patients. Conversion of SI to
traditional units: 1 juM =454 ng/ml.
radioimmunoassay using the principle of
competitive protein binding (1125 MTX-
RIA, Uniscience, Cambridge).
Results are shown in Figs 1 and 2. There
was wide variation in peak concentrations
(0-28-1-6 pM) with a mean of 1-01 IuM.
The timing of the peak value ranged from
0.5 to 4 h after administration, mean 1.5 h.
Fig. 2 shows the absorption patterns of 6
patients (30%) who had serum levels less
than 0 44 uM at 1 h and who could be
classified as slow absorbers (Craft, 1979).
After 1 h there was wide variation in the
absorption pattern, 3 patients reaching
high peak levels which were greater than
the mean for the group as a whole.
It seems clear from these observations
that a lh serum MTX level may not
accurately reflect the overall serum profile.
In contrast to the observations of Free-
man-Narrod (1962) the slow absorber may
reach high peak levels indicating adequate
absorption, despite a low level at 1 h. At
this early stage the serum level may be
influenced by several factors, such as the
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FIG. 2.-Methotrexate absorption patterns in
slow absorbers, with one hour levels less
than 0 44 /LM. Conversion: SI to traditional
units-I pM=454 ng/ml.
rate of gastric emptying and small intes-
tinal motility, as well as the rates ofintra-
vasculardistribution andexcretion. Itmay
be important to determine which of these
factors contribute to an early low level, if
in fact the slow absorber is predisposed to
early disease relapse (Craft, 1979). A more
extended analysis of the absorption/
excretion profile would provide informa-
tion such as the absorption rate constant,
elimination rate constant and the area
under the curve. It might more logically be
these derivations which would be corre-
lated with response to therapy and rate of
relapse. Moreover, although this study
was carried out in the fasting state, in-
vestigation of the influences of differing
nutrients taken in association with the
drug is being carried out, as these may
significantly alter absorption (Krondl,
1970).
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On the basis of random sampling and
division into fast or slow absorbers it
would be unwise at present to alter metho-
trexate therapy either in terms of dosage
or route ofadministration. Although infor-
mation can be obtained from short-term
studies such as this, it is preferable that
data be obtained from a more extended
study, to permit accurate pharmaco-
kinetic analysis.
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